Apalutamide and Dasatinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A induction can accelerate dasatinib clearance and reduce exposure.
Clinical significance and safety
Apalutamide contains apalutamide, a strong CYP3A inducer. It may lower dasatinib exposure and reduce cancer treatment effectiveness. The prescribing team should review alternatives and product-specific management rather than relying on a dosing-time change.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.